|
Listen to this story:
|
Andre Watson, CEO and founder of Ligandal, joined ESG News at the World Economic Forum to share insights on a new frontier in precision medicine: targeted drug delivery. With a background in biomedical engineering and nanoscience, Watson is leading efforts to solve a fundamental challenge in modern healthcare—how to direct therapies like CRISPR and mRNA to specific organs and tissues with precision. Most existing technologies, he explains, lack the ability to reach the intended destination within the body, often leading to side effects or ineffective outcomes.
Ligandal is developing a platform that addresses these logistical gaps, aiming to enable therapeutic delivery across up to 70 organs and tissues. With wide-reaching applications across drug types and modalities, this advancement positions the company for long-term institutional engagement in the healthcare and biotech sectors. As precision delivery becomes more viable, the intersection of science, scalability, and investment will be key to unlocking next-generation medical solutions.
Key Highlights
- Ligandal focuses on solving molecular logistics in drug delivery.
- Technologies like CRISPR and mRNA are powerful but currently lack precision targeting.
- Ligandal’s platform enables organ- and tissue-specific delivery.
- Targeting up to 70 tissues/organs in the next two years.
- Compatible across multiple modalities: drugs, gene editors, mRNA, and more.
- Positioned as a long-term institutional investment opportunity in precision healthcare.
- Watson’s background in gene delivery began with research in 2011.
ESG News coverage of the World Economic Forum was made possible by; FilmHedge, a leader in Film & TV financing.